Literature DB >> 34918942

The role of nutritional assessment for predicting radiotherapy-induced adverse events in patients with gastric cancer.

Wenjie Sun1,2, Guichao Li1,2, Jing Zhang1,2, Ji Zhu1,2, Zhen Zhang1,2.   

Abstract

OBJECTIVE: The aim of this study was to investigate the role of nutritional factors in predicting radiotherapy-associated toxicities for gastric cancer patients.
METHODS: A total of 285 gastric cancer patients who underwent radiotherapy in our hospital (Fudan University Shanghai Cancer Center) between 2010 and 2017 were included in this retrospective study. Nutritional status assessment included body weight loss (BWL), body mass index (BMI), serum albumin, nutrition risk screening 2002(NRS-2002), patient-generated subjective global assessment(PG-SGA) and nutritional risk index (NRI).
RESULTS: Of all patients, 19.6% were underweight (BMI<18.5 kg/m2), 25.6% were hypoalbuminemia (<35 g l-1) and 48.8% lost ≥10% of body weight in the 6-month interval before radiotherapy(BWL). Meanwhile, 73.3%, 78.6 and 47.2% of the patients were diagnosed as malnutrition based on NRS-2002, PG-SGA and NRI, respectively. Hematological adverse events were present in 91.2% (≥Grade 1) and 20.4% (≥Grade 3) of the patients. Non-hematological adverse events occurred in 89.8% (≥Grade1) and 14.4% (≥Grade 3) of the patients. Multivariate analyses indicated that only hypoalbuminemia(<35 g l-1) was independent predictor for Grade 3/4 hematological and non-hematological adverse events. Meanwhile, higher BWL(≥10%) was also independent predictor for Grade 3/4 non-hematological adverse events. NRS-2002, PG-SGA and NRI score were not associated with treatment-induced adverse events.
CONCLUSION: BWL and serum albumin are useful factors for predicting severe adverse events in gastric cancer patients who undergo radiotherapy. ADVANCES IN KNOWLEDGE: The use of nutritional factors in predicting severe adverse events enables implementation of individualized treatment strategies for early and intensive nutritional interventions in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34918942      PMCID: PMC8822561          DOI: 10.1259/bjr.20201004

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  22 in total

1.  Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients.

Authors:  I Bosaeus; P Daneryd; E Svanberg; K Lundholm
Journal:  Int J Cancer       Date:  2001-08-01       Impact factor: 7.396

2.  [Association of nutrition with treatment compliance and toxicities in patients undergoing chemoradiation after gastrectomy].

Authors:  Qi-wen Li; Gui-chao Li; Ya-nong Wang; Zi-wen Long; Xiao-wen Liu; Zhen Zhang
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2013-06

3.  Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study.

Authors:  Maximilien Barret; David Malka; Thomas Aparicio; Cécile Dalban; Christophe Locher; Jean-Marc Sabate; Samy Louafi; Touraj Mansourbakht; Franck Bonnetain; Alain Attar; Julien Taieb
Journal:  Oncology       Date:  2012-01-20       Impact factor: 2.935

4.  Pre-therapeutic nutritional assessment for predicting severe adverse events in patients with head and neck cancer treated by radiotherapy.

Authors:  Takeyuki Kono; Koji Sakamoto; Seiichi Shinden; Kaoru Ogawa
Journal:  Clin Nutr       Date:  2016-11-05       Impact factor: 7.324

5.  The nutritional assessment of head and neck cancer patients.

Authors:  Mauro Magnano; Patrizia Mola; Giacomo Machetta; Paola Maffeis; Ilenia Forestiero; Roberta Cavagna; Elena Artino; Paolo Boffano
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-23       Impact factor: 2.503

6.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

7.  Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer.

Authors:  J Bauer; S Capra; M Ferguson
Journal:  Eur J Clin Nutr       Date:  2002-08       Impact factor: 4.016

8.  The correlation of nutrition risk index, nutrition risk score, and bioimpedance analysis with postoperative complications in patients undergoing gastrointestinal surgery.

Authors:  Marc Schiesser; Philipp Kirchhoff; Markus K Müller; Markus Schäfer; Pierre-Alain Clavien
Journal:  Surgery       Date:  2009-03-27       Impact factor: 3.982

9.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  The impact of nutritional status, nutritional risk, and nutritional treatment on clinical outcome of 2248 hospitalized cancer patients: a multi-center, prospective cohort study in Chinese teaching hospitals.

Authors:  Hongming Pan; Sanjun Cai; Jiafu Ji; Zhiwei Jiang; Houjie Liang; Feng Lin; Xiyong Liu
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

View more
  2 in total

1.  Prognostic value of the controlling nutritional status score in patients with myelodysplastic syndromes.

Authors:  Qiuni Chen; Kankan Chen; Sumei Wang; Lijuan Zhang; Yuye Shi; Shandong Tao; Zhengmei He; Chunling Wang; Liang Yu
Journal:  Front Nutr       Date:  2022-07-27

2.  Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients.

Authors:  Yue Zhao; Zhengzheng Ji; Jiasong Li; Shasha Zhang; Chensi Wu; Ruixing Zhang; Zhanjun Guo
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.